There is an increasing need to quickly publish emerging clinical evidence supporting novel treatments and medications and extend the reach of key medical claims to new target audiences.
pharma digital publication planning
It’s estimated $58.8 billion USD is invested every year in R&D by pharma companies in the United States, yet only a fraction of the data from clinical trials and real-world studies are translated into articles published in medium- or high-tier journals.
While the reasons vary, it’s getting harder to publish in prestigious journals because of: the rise of “chaperoned” publication writing; a lack of dedicated on-demand; in-house publication professionals, and; cumbersome, lengthy publication development timelines.KOLs, HCPs and PIs leading publication writing efforts for sponsor pharmaceutical companies often have conflicting demands on their time and have a hard time staying on top of the literature and advances in new treatment guidelines. To improve the efficiency of publication writing, the pharmaceutical industry partners with CROs, publication houses and medical communications agencies to:
- Generate tactical publication plans
- Conduct literature gap analyses
- Provide authorship support
With more stakeholders and support involved, this process can often lead to time-consuming, labour-intensive email correspondence that routinely fails to engage authors. Bottlenecks are created that elongate the publication development timeline, leading to author frustration and unmet expectations for the sponsor pharmaceutical company.